Form 4: Emergent BioSolutions Director Kathryn C. Zoon Reports Acquisition of Stock Options and Restricted Stock Units

Director Kathryn C. Zoon reports acquisition of stock options and restricted stock units in Emergent BioSolutions Inc.

Summary

• Kathryn C. Zoon, a director of Emergent BioSolutions Inc., filed a Form 4 on May 28, 2024, reporting transactions that occurred on May 23, 2024.
• Zoon acquired 17,430 shares of common stock through restricted stock units (RSUs) and 25,748 stock options.
• The RSUs were granted under the company's Stock Incentive Plan and will vest on the day prior to the one-year anniversary of the grant date, contingent upon Zoon remaining a board member.
• The stock options, also granted under the Stock Incentive Plan, will vest on the same date as the RSUs and have an exercise price of $5.02.
• Following these transactions, Zoon beneficially owns 66,312 shares of common stock and 25,748 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard compensation practices and aligns director interests with shareholders. There are no indications of negative events or concerns.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting requirements incentivize continued service on the board of directors.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of RSUs and stock options is contingent upon continued service on the board.

Industry Context

This filing is a routine disclosure of stock grants to a company director, which is a common practice in publicly traded companies to align management and shareholder interests.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for directors in publicly traded companies like Emergent BioSolutions.
• The vesting schedules, typically one year, are also common to ensure continued service and alignment with company performance.
• Comparable companies such as Moderna, Novavax, and BioNTech also utilize stock options and RSUs as part of their director compensation packages.

Stakeholder Impact

• The grant of stock options and RSUs can positively impact shareholders by aligning the interests of the director with the company's long-term success.

Key Dates